Relay Therapeutics is trading 4.03% lower at $18.57, with no identified company-specific announcement explaining the September 23 decline.
- The decline reverses part of the 6.38% gain recorded on September 22, 2026.
- X-Chem announced a September 22 milestone tied to Relay’s Phase 3 zovegalisib trial; this positive development does not directly explain the drop.
- Broader indexes are modestly lower, while biotech is higher.